Skip to main content
CND In the News

Alpha-Synuclein Detection Research Featured in Medscape Interview

Alpha-Synuclein Detection Research Featured in Medscape Interview

Dr. Christopher H. Gibbons, Senior Scientific Advisor of CND Life Sciences, was recently interviewed in a Medscape Neurology story titled “Skin Testing May Help Detect Movement Disorders.”

In the interview, Dr. Gibbons describes research he presented at this year’s American Academy of Neurology examining how phosphorylated alpha-synuclein (p-syn) testing can contribute to the diagnosis and management of synucleinopathies. In the study, a panel of physicians reviewed the medical histories of patients with suspected synucleinopathies and determined if they had a probable or possible diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or undifferentiated synucleinopathy. P-syn testing was performed using the Syn-One Test®, and the results were compared to the physician panel’s determination.

Dr. Gibbons also discusses the types of cases where clinicians might consider using the Syn-One Test in their practice to help clarify the diagnosis and management of a synucleinopathy and how testing for p-syn can contribute to the search for disease-modifying therapies.

Watch the interview

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.